Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
← catalyst calendarNCT07753148 · readout in 1,720 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
52estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-17 | estimated | When the study began enrolling |
| Primary completion | 2031-05-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-05-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Clonal Cytopenia of Undetermined Significance (CCUS)
- Low-Risk Myelodysplastic Syndrome (LR-MDS)
Intervention
- Drug: REGN17235
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Treatment Emergent Adverse Events (TEAEs)
measured Up to 5 years
Severity of TEAEs
measured Up to 5 years
Occurrence of Serious Adverse Events (SAEs)
measured Up to 5 years
Severity of SAEs
measured Up to 5 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed